Path, Genocea, and Richard Malley, associate professor of Pediatrics at Children’s Hospital Boston, will collaborate on a protein-subunit pneumococcal vaccine for use in the developing world. Mark Alderson,
GPI-04-0001 is a Phase IIb, non-randomized, open-label, single-arm international, multi-center registration study designed to evaluate the efficacy, safety and tolerability of romidepsin as a treatment for cutaneous T-cell
Fiscal 2009 Outlook Saxelby concluded, I am very pleased with the progress we’ve made in the first half of fiscal 2009. Landauer’s performance demonstrates the success of our
The new capital will be used for growth initiatives and general corporate purposes. Frist Capital is a private investment company investing the assets of a Nashville family. Matthew
Standing Stone’s DMClinic will help hospitals, clinics and other healthcare facilities manage their inpatient and outpatient diabetic patients. The full-featured software combines point-of-service testing for HgbA1C and glucose
The grant will support additional studies in rodents and non-human primates to further characterize the high-level protection observed previously in these species. Work completed during the first grant
Nephros is now in the process of preparing its submission to the FDA under section 510(k) of the Food, Drug And Cosmetics Act to obtain approval to sell
Del Medical’s Universal brand DCChoice provides expediency and flexibility for a small or start-up chiropractor’s office, resulting in lower overhead costs for the practitioner, according to Del Global
The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment
The submission is based on new information from the company’s completed Phase III trial that showed, among other findings, a significant increase in overall survival for patients who
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.